Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 21;59(7):1183.
doi: 10.3390/medicina59071183.

Epithelial Ovarian Cancer: A Five Year Review

Christos Arnaoutoglou  1 , Kalliopi Dampala  1 , Christos Anthoulakis  1 , Evangelos G Papanikolaou  2 , Ioannis Tentas  3 , Georgios Dragoutsos  4 , Nikolaos Machairiotis  5 , Paul Zarogoulidis  6 , Aristeidis Ioannidis  7 , Dimitris Matthaios  8 , Eleni I Perdikouri  9 , Dimitrios Giannakidis  10 , Chrysanthi Sardeli  11 , Stamatios Petousis  12 , Panagoula Oikonomou  13 , Christina Nikolaou  13 , Charalampos Charalampidis  14 , Konstantinos Sapalidis  6
Affiliations
Review

Epithelial Ovarian Cancer: A Five Year Review

Christos Arnaoutoglou et al. Medicina (Kaunas). .

Abstract

Ovarian cancer is a malignant disease that affects thousands of patients every year. Currently, we use surgical techniques for early-stage cancer and chemotherapy treatment combinations for advanced stage cancer. Several novel therapies are currently being investigated, with gene therapy and stem cell therapy being the corner stone of this investigation. We conducted a thorough search on PubMed and gathered up-to-date information regarding epithelial ovarian cancer therapies. We present, in the current review, all novel treatments that were investigated in this field over the past five years, with a particular focus on local treatment.

Keywords: cancer; gene therapy; local treatment; ovarian cancer; prognostic factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
It is known that ovarian cancer is often diagnosed at a late stage. Stem cell dysfunction or reproduction dysregulation is the main reason for ovarian cancer growth. Surgery and chemotherapy is possible for early-stage disease; however, 60% of the patients experience disease relapse during the following 12–18 months. Finally chemotherapy resistance is observed in 80–90% of all patients.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Doll K.M., Rademaker A., Sosa J.A. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018;153:588–589. doi: 10.1001/jamasurg.2018.0501. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA A Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA A Cancer J. Clin. 2011;61:183–203. doi: 10.3322/caac.20113. - DOI - PMC - PubMed
    1. Elzakkers J.C.J., van der Aa M.A., van Altena A.M., de Hullu J.A., Harmsen M.G. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. Gynecol. Oncol. 2019;155:213–219. doi: 10.1016/j.ygyno.2019.08.018. - DOI - PubMed

MeSH terms

Substances